A fifty-eight-year-old white man was diagnosed as having an adenocarcinoma of the prostate (grade III by the U.T.M.D. Anderson Hospital grading system). Five years after the initial diagnosis and three months after signs and symptoms of the myasthenic syndrome of Eaton-Lambert (MSEL), he was found to have a small cell carcinoma of the prostate. Histologic examination showed adenocarcinoma merging into a small cell carcinoma component of intermediate cell type. Immunostaining was positive for neuroendocrine markers--namely, neuron-specific enolase and serotonin--and was limited to the small cell carcinoma component. This is the first report of a patient with small cell carcinoma of the prostate presenting with MSEL. Our findings support prior observations of a strong propensity for small cell carcinoma to be associated with paraneoplastic syndromes, regardless of the initial location of the tumor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0090-4295(89)90017-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hierarchical Selenium-Doped Nickel-Cobalt Hybrids on Carbon Paper for the Overall Water-Splitting Electrocatalytic System.
ACS Appl Mater Interfaces
January 2025
Department of Battery and Chemical Engineering, Hanyang University, Ansan, Gyeonggi-do 15588, Republic of Korea.
Designing and constructing hierarchically structured materials with heterogeneous compositions is the key to developing an effective catalyst for overall water-splitting applications. Herein, we report the fabrication of hollow-structured selenium-doped nickel-cobalt hybrids on carbon paper as a self-supported electrode (denoted as Se-Ni|Co/CP, where Ni|Co hybrids consist of nickel-cobalt alloy-incorporated nickel-cobalt oxide). The procedure involves direct growth of zeolitic imidazolate framework-67 (ZIF-67) on bimetal-based nickel-cobalt hydroxide (NiCoOH) electrodeposited on CP, followed by selenous etching and pyrolysis to obtain the final Se-Ni|Co/CP electrocatalytic system.
View Article and Find Full Text PDFImmunohistochemistry-based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy.
J Pathol Clin Res
January 2025
Department of Urology, University of Duisburg-Essen, Essen, Germany.
Distinct molecular subtypes of muscle-invasive bladder cancer (MIBC) may show different platinum sensitivities. Currently available data were mostly generated at transcriptome level and have limited comparability to each other. We aimed to determine the platinum sensitivity of molecular subtypes by using the protein expression-based Lund Taxonomy.
View Article and Find Full Text PDFNovel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses.
Curr Med Chem
January 2025
Shree S K Patel College of Pharmaceutical Education and Research, Ganpat University, Mahesana, Gujarat, 384012, India.
Therapeutic hurdles persist in the fight against lung cancer, although it is a leading cause of cancer-related deaths worldwide. Results are still not up to par, even with the best efforts of conventional medicine, thus new avenues of investigation are required. Examining how immunotherapy, precision medicine, and AI are being used to manage lung cancer, this review shows how these tools can change the game for patients and increase their chances of survival.
View Article and Find Full Text PDFMitochondrial DNA Mutations as a Factor in the Heritability of Atherosclerosis and Other Diseases.
Curr Med Chem
January 2025
Laboratory of Angiopathology Institute of General Pathology and Pathophysiology, 8, Baltiiskaya Street, 125315, Moscow, Russia.
This review discusses the possibility of inheritance of some diseases through mutations in mitochondrial DNA. These are examples of many mitochondrial diseases that can be caused by mutations in mitochondrial DNA. Symptoms and severity can vary widely depending on the specific mutation and affected tissues.
View Article and Find Full Text PDFCell type-specific upregulation of NKG2D ligand MICA in response to APTO253.
Ann Transl Med
December 2024
Institute for Tumor Immunology, Center for Tumor Biology and Immunology, Philipps-University Marburg, Marburg, Germany.
One of the most important targets for natural killer (NK) cell-mediated therapy is the induction of natural killer group 2D ligand (NKG2D-L) expression. APTO253 is a small molecule that selectively kills acute myeloid leukemia (AML) cells, and it has been reported that APTO253 can induce Krüppel-like factor 4 (KLF4) expression and downregulate c-MYC expression. Recently, we discovered a novel role of APTO253 in modulating the NK cell response by inducing surface expression of NKG2D-Ls, especially MHC class I polypeptide-related sequence A (MICA), in AML cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!